Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etonogestrel-releasing IUS · SCH 900342, ORG 299001

Other · developed by Organon and Co

Phase 2 Most advanced trial (none active)
OGN Developer
1 Registered trials

What is Etonogestrel-releasing IUS?

Etonogestrel-releasing intrauterine system (SCH 900342, ORG 299001) is a drug delivery device that releases etonogestrel, a progestin, within the uterus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SCH 900342, ORG 299001
Drug type
Other
Therapy area
Women's health
Developer
Organon and Co (OGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00967746 Phase 2 Contraception Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Contraception

More from Organon and Co

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Etonogestrel-releasing IUS

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.